ArticleFrontiers in bioinformatics2021
COVID-19 Multi-Targeted Drug Repurposing Using Few-Shot Learning.
Article in Frontiers in bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Artificial Intelligence-Guided Phenotypic Drug Repurposing Against Streptococcus pneumoniae.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- AI-genomics synergy for drug repurposing in breast cancer: an interpretability-driven framework.NPJ genomic medicine · 2026Review
- Semi-supervised meta-learning elucidates understudied molecular interactions.Communications biology · 2024Article
- A gastrointestinal locally activating Janus kinase inhibitor to treat ulcerative colitis.The Journal of biological chemistry · 2023Article
- Hierarchical multi-omics data integration and modeling predict cell-specific chemical proteomics and drug responses.Cell reports methods · 2023Article
- CoGT: Ensemble Machine Learning Method and Its Application on JAK Inhibitor Discovery.ACS omega · 2023Article
- End-to-end sequence-structure-function meta-learning predicts genome-wide chemical-protein interactions for dark proteins.PLoS computational biology · 2023Article
- Hybrid Approach to Identifying Druglikeness Leading Compounds against COVID-19 3CL Protease.Pharmaceuticals (Basel, Switzerland) · 2022Article
- A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Reinforcement learning for systems pharmacology-oriented and personalized drug design.Expert opinion on drug discovery · 2022Review
- Exploration of chemical space with partial labeled noisy student self-training and self-supervised graph embedding.BMC bioinformatics · 2022Article
- DeepREAL: a deep learning powered multi-scale modeling framework for predicting out-of-distribution ligand-induced GPCR activity.Bioinformatics (Oxford, England) · 2022Article
- Optimal COVID-19 therapeutic candidate discovery using the CANDO platform.Frontiers in pharmacology · 2022Article
- Deep Learning Algorithms Achieved Satisfactory Predictions When Trained on a Novel Collection of Anticoronavirus Molecules.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The life-threatening disease COVID-19 has inspired significant efforts to discover novel therapeutic agents through repurposing of existing drugs. Although multi-targeted (polypharmacological) therapies are recognized as the most efficient approach to system diseases such as COVID-19, computational multi-targeted compound screening has been limited by the scarcity of high-quality experimental data and difficulties in extracting information from molecules. This study introduces
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.